

## Minutes

**Date** Wednesday, 01/07/2020

**Time** 08.30am

**To** Committee Members

**At** Virtual via Microsoft Teams

**Subject** AWERB 3Rs Committee

**In Attendance:**

**Apologies:**

**1. Minutes**

The previous minutes were approved.

**2. Matters Arising**

None

**3. Retrospective Reviews**

The committee discussed the following:

[REDACTED] - Mitochondrial function in metabolic disease

The committee praised the positive engagement of the PPL holder with the retrospective review. The committee acknowledged the effort to provide clear and comprehensive information.

- Section 3.1: The committee would like to know how the use of human information has been able to replace animals. Can further information about this be provided? Were there any questions in this PPL that have been answered using the human data that was previously going to be addressed using animals?
- Section 3.7: The refinement of the intraperitoneal injection seems a more technical refinement than a welfare refinement. The improvement of the reproducibility between injections has very likely reduced the number of animals used. The committee advises the PPLh to move this information in to the reduction section. Since this is, an important refinement the committee wondered if the PPLh would be prepared to provide a brief document that we could use to underpin the rolling out of this refinement.
- Section 3.8: The committee would be interested to know how often the body temperature was measured by the microchip.
- Section 4.8: The committee noted no publication was in bold. However, some refinement approaches were presented in the RR and the committee wondered if these were or will be reported in some future publications?



██████████ - Mitochondrial diseases: pathogenesis and therapy

- Section 2.1: The committee has noted that for some protocols the number of animals reported is already at a third of the estimation. The committee is advising the PPLh to review any future work plan in light of the number of animals already used and to amend the animal number estimation, if necessary.
- Section 2.2: The committee acknowledge the mortality in the breeding protocol is low, however would be interested to know the proportion of Fbxl4 mice that contributed to this mortality rate and what steps have been taken to investigate and address this mortality.
- Section 2.10: The committee understand that some mouse strains have a very aggressive behaviour leading to single housing. The committee would like to know if there are currently any investigations in to how to resolve this issue in FVB mice.
- Section 3.2: The reduction of animals (30-40%) is essential information. The committee advised that more details with number of animals per protocol would be suitable and provide a better idea of the magnitude of the reduction.
- Section 3.6: The committee felt this section was slightly confusing and advised rephrasing it highlighting the good molecular reproduction of the pathophysiology.
- Section 3.7: This section is reporting some refinement. The committee would like to know if some of these techniques are novel and will therefore be published. If a manuscript is in preparation please report it in section 4.8
- Section 3.8: The committee was confused by some terms used such as “humping” or “runting” and advised to review them or provide a short description or if these are typographical errors that these are corrected.

**4. Retrospective Assessments**

(a) None

**5. Project Licence Applications**

(a) None

**6. Severe Severity licence reviews**

None

**7. Standard Condition 18 reports**

None

**8. 3Rs information/reports**

████ reported that NC3Rs have released information about their webinars; they have two coming up that █████ will circulate information about. █████ has shared some information about bone marrow transplants, █████ will circulate this information also. █████ has some information from █████ at MRC-LMB about the stereotactic injection technique. █████ informed the committee that the Newcastle group have been doing some work on the rabbit grimace scale and has forwarded that information to the NACWOs working with rabbits.

**9. Feedback from previous Retrospective Reviews\***

None



**10. Minutes of AOC meeting\***

None

**11. Minutes of AWERB Standing meeting\***

None

**12. Any Other Business**

**Date of next meeting:** Wednesday 5<sup>th</sup> August 2020

**\*Items for information only unless un-starred by committee member**